Dan Iosifescu, M.D., M.Sc.
Dr. Dan Iosifescu is the Director of Clinical Research at the Nathan Kline Institute and Associate Professor of Psychiatry at the New York University School of Medicine. His research is focused on novel pharmacological treatments (such as ketamine and other glutamatergic drugs) and devices (such as novel forms of magnetic stimulation) for patients with severe mood disorders (major depression and bipolar disorder). In his research, Dr. Iosifescu uses neuroimaging (MRI, MRS) and neurophysiology (quantitative EEG) techniques to evaluate structural, biochemical, and functional brain abnormalities in mood disorders and their impact on clinical treatment. In parallel, Dr. Iosifescu also focuses on the recognition and treatment of cognitive deficits associated with mood disorders.
After completing medical studies at the “Carol Davila” University in Bucharest, Romania, Dr. Iosifescu completed his internship and psychiatry residency at Massachusetts General Hospital (MGH) and McLean Hospital. His research training included a neuroimaging fellowship in the Neuroscience Laboratory at Harvard Medical School, a psychopharmacology fellowship in the MGH Mood and Anxiety Disorders Institute, and a fellowship in the Clinical Investigator Training Program at Harvard and MIT. In parallel, Dr. Iosifescu received a Master of Medical Science degree from Harvard University. Dr. Iosifescu was Associate Professor of Psychiatry at Harvard Medical School and a researcher at MGH until 2010; he then was the Director of the Mood and Anxiety Disorders Program and Associate Professor of Psychiatry and Neuroscience at the Icahn School of Medicine at Mount Sinai.
Dr. Iosifescu has authored more than 100 papers in peer-reviewed medical journals, 14 book chapters and more than 100 abstracts. He has received a series of prestigious prizes: the NARSAD Young Investigator Award (which he received twice), the Kaplen Award and the Livingston Award from Harvard Medical School, the American Psychiatric Association Young Investigator Award, the NCDEU New Investigator Award, and a National Institute for Mental Health K23 Career Development Award. Dr. Iosifescu has also been designated among the “Best Doctors in America” in all editions of “Best Doctors” since 2005, and among the Top Doctors in Castle Connolly’s psychiatry section.
Harper DG, Jensen JE, Ravichandran C, Perlis RH, Fava M, Renshaw PF, Iosifescu DV. Tissue Type Specific Bioenergetic Abnormalities in Adults with Major Depression. Neuropsychopharmacology. 2016 Sep 2. doi: 10.1038/npp.2016.180.
Murrough JW, Collins KA, Fields J, DeWilde KE, Phillips ML, Mathew SJ, Wong E, Tang CY, Charney DS, Iosifescu DV. Regulation of neural responses to emotion perception by ketamine in individuals with treatment-resistant major depressive disorder. Transl Psychiatry. 2015 Feb 17;5:e509.
Cassano P, Cusin C, Mischoulon D, Hamblin MR, De Taboada L, Pisoni A, Chang T, Yeung A, Ionescu DF, Petrie SR, Nierenberg AA, Fava M, Iosifescu DV. Near-Infrared Transcranial Radiation for Major Depressive Disorder: Proof of Concept Study. Psychiatry J. 2015:352979. doi: 10.1155/2015/352979. Epub 2015 Aug 19.
Iosifescu DV. Maintaining the initial clinical response after ketamine in bipolar and unipolar depression: an important next-step challenge. J Clin Psychiatry. 2015 Jun;76(6):738-40
Murrough JW, Burdick KE, Levitch CF, Perez AM, Brallier JW, Chang LC, Foulkes A, Charney DS, Mathew SJ, Iosifescu DV. Neurocognitive Effects of Ketamine and Association with Antidepressant Response in Individuals with Treatment-Resistant Depression: A Randomized Controlled Trial. Neuropsychopharmacology. 2015 Mar 13;40(5):1084-90